Once-monthly pegylated epoetin beta versus darbepoetin alfa every two weeks in renal transplant recipients: A randomized Trial

Transplantation

Volumn 95, Issue 2, 2013, Pages

  Campistol, Josep M ^a   Carreño, Agustín ^b   Morales, José M ^c   Pallardó, Luis ^d   Franco, Antonio ^e   Navarro, Dolores ^f   Grinyó, Josep M ^a   Montenegro, Jesús ^g   Sánchez Fructuoso, Ana I ^h   Romero, Ramón ⁱ   Guirado, Luis ^j   Arias, Manuel ^k  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^g Hospital Galdakano Vizcaya   (Spain)

^h HOSPITAL CLÍNICO SAN CARLOS   (Spain)

ⁱ HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^j FUNDACIÓ PUIGVERT   (Spain)

^k HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CREATININE; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; IRON DEFICIENCY; KIDNEY TRANSPLANTATION; LETTER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PAIN; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

AGED; ANEMIA; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RENAL INSUFFICIENCY, CHRONIC; SPAIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872899414     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182782f3a     Document Type: Letter

References (15)

1. Dellanna F, Winkler RE, Bozkurt F, et al. Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study. Int J Clin Pract 2011; 65: 64.
2. Fliser D, Kleophas W, Dellanna F, et al. Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study. Curr Med Res Opin 2010; 26: 1083.
3. Imbasciati E, Bernardo M, Caraman PL, et al. Stable haemoglobin (Hb) levels are maintained with once-monthly C.E.R.A. in dialysis patients with varying C-reactive protein (CRP), albumin or dialysis adequacy. Nephrol Dial Transplant 2007; 22: vi412.
4. Levin NW, Fishbane S, Canedo FV, et al. Intravenous methoxy polyethylene glycolepoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007; 370: 1415.
5. Locatelli F, Villa G, de Francisco AL, et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin 2007; 3: 969.
6. Mann J, Locatelli F, Sulowicz W, et al. C.E.R.A. provides stable haemoglobin (Hb) levels in CKD patients on dialysis with and without coronary artery disease (CAD) or diabetes mellitus (DM) when administered once monthly. Nephrol Dial Transplant 2007; 22: vi409.
7. Sulowicz W, Locatelli F, Ryckelynck JP, et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007; 2: 637.
8. Provenzano R, Besarab A, Macdougall IC, et al. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clin Nephrol 2007; 67: 306.
9. Roger SD, Locatelli F, Woitas RP, et al. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrol Dial Transplant 2011; 26: 3980.
10. Carrera F, Lok CE, de Francisco A, et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant 2010; 25: 4009.
11. Sanchez-Fructuoso A, Guirado L, Ruiz JC, et al. Anemia control in kidney transplant patients treated with methoxy polyethylene glycol-epoetin beta (Mircera): the Anemiatrans Group. Transplant Proc 2010; 42: 2931.
12. MIRCERA\ Summary of Product Characteristics. 2007. F. Hoffmann-La Roche Ltd.
13. Canaud B, Mingardi G, Braun J, et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 2008; 23: 3654.
14. Macdougall IC, Walker R, Provenzano R, et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol 2008; 3: 337.
15. Locatelli F, Mann JF, Aldigier JC, et al. C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease. Clin Nephrol 2010; 73: 94.